Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy

G Paraskevopoulos; E Sifnaios; K Christodoulopoulos; F Mantopoulou; M Papakonstantis; D Sabaziotis

Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy

Eur Ann Allergy Clin Immunol. 2013 Apr;45(2):52-5.

Authors

G Paraskevopoulos¹, E Sifnaios, K Christodoulopoulos, F Mantopoulou, M Papakonstantis, D Sabaziotis

Affiliation

¹ Allergy and Clinical Immunology Department, 401 General Military Hospital of Athens, Greece.

PMID: 23821833

Abstract

Mastocytosis is a clonal disease derived from hematopoietic bone marrow progenitor cells. Clinical manifestations of the disease vary greatly depending on tissue involvement. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody licensed in the treatment of asthma with increasing reports of clinical eficiency in other allergic diseases. We describe a case of a patient with mastocytosis responsive clinically and patho-physiologically after anti-IgE treatment.

Publication types

Case Reports

MeSH terms

Adult
Anaphylaxis / drug therapy*
Anaphylaxis / immunology
Anti-Allergic Agents / therapeutic use*
Antibodies, Anti-Idiotypic / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Male
Mast Cells / drug effects*
Mast Cells / immunology
Mastocytosis / drug therapy*
Mastocytosis / immunology
Omalizumab
Skin / drug effects*
Skin / immunology
Treatment Outcome

Substances

Anti-Allergic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
anti-IgE antibodies
Omalizumab